Partner at Novo's venture fund sued over unsuccessful billion-kroner investment

Thomas Dyrberg, managing partner in Novo Ventures, is one of eight people being sued in an American case over alleged misleading of investors in the botched biotech firm Ophthotech, which at one point was Novo Ventures’ biggest single investment.

Thomas Dyrberg, leading partner in Novo Ventures, is the eighth person to be accused of misleading investors in biotech firm Ophthotech Photo: Novo Holdings/ PR

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try us for 14 days

Try a trial subscription for access to our quality journalism

Related articles